[Form 4] Cidara Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cidara Therapeutics (CDTX) director Theodore R. Schroeder received a stock option grant on June 18, 2025. The key details of this insider transaction include:

• Granted 11,100 stock options to purchase common stock
• Exercise price set at $21.31 per share
• Options will vest on the earlier of:
  • June 18, 2026, or
  • Day before the 2026 annual stockholder meeting
• Options expire on June 17, 2035

This grant appears to be part of the company's regular director compensation program. The Form 4 was filed by Shane Ward as attorney-in-fact for Mr. Schroeder, reporting the transaction in compliance with SEC regulations for insider trading disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schroeder Theodore R

(Last) (First) (Middle)

C/O CIDARA THERAPEUTICS, INC.

6310 NANCY RIDGE DRIVE SUITE 101

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cidara Therapeutics, Inc. [ CDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$21.31	06/18/2025		A		11,100		(1)	06/17/2035	Common Stock	11,100	$0	11,100	D

Explanation of Responses:

1. The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders.

Remarks:

	/s/ Shane Ward, Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did CDTX director Theodore Schroeder receive in June 2025?

Theodore Schroeder received 11,100 stock options on June 18, 2025, with an exercise price of $21.31 per share. These options expire on June 17, 2035 and will vest on either June 18, 2026, or the day before CDTX's 2026 annual meeting of stockholders, whichever comes first.

When do Theodore Schroeder's CDTX stock options vest?

The stock options will vest on the earlier of two dates: (i) June 18, 2026 or (ii) the day before Cidara Therapeutics' 2026 annual meeting of stockholders.

What is the exercise price of CDTX's June 2025 director stock options?

The stock options granted to director Theodore Schroeder have an exercise price of $21.31 per share.

How many CDTX stock options does Theodore Schroeder beneficially own after the June 2025 grant?

Following the reported transaction, Theodore Schroeder beneficially owns 11,100 stock options of CDTX directly (indicated as ownership form 'D' in the filing).

When do Theodore Schroeder's CDTX stock options expire?

The stock options granted to Theodore Schroeder expire on June 17, 2035, ten years after the grant date.